Niall O’Donnell's Insider Trades & SAST Disclosures
Niall O’Donnell's most recent trade in Reneo Pharmaceuticals Inc was a trade of 17,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 6, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Niall O’Donnell.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Spruce Biosciences Inc | Niall O’Donnell | Director | 25 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 08 May 2023 | 125,000 | 2,188,713 | - | 8 | 1,000,000 | Common Stock |
| Spruce Biosciences Inc | Niall O’Donnell | Director | 16 Feb 2023 | 630,400 | 1,326,305 | - | 3.2 | 1,998,368 | Common Stock | |
| Spruce Biosciences Inc | Niall O’Donnell | Director | 16 Feb 2023 | 472,800 | 472,800 | - | - | Common Stock Warrant (Right to Buy) | ||
| Mirum Pharmaceuticals Inc | Niall O’Donnell | Director | Sale of securities on an exchange or to another person at price $ 19.99 per share. | 11 Nov 2022 | 174,121 | 1,746,997 (6%) | 0% | 20.0 | 3,481,410 | Common Stock |
| Mirum Pharmaceuticals Inc | Niall O’Donnell | Director | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 11 Nov 2022 | 93,770 | 1,621,118 (6%) | 0% | 19.7 | 1,846,022 | Common Stock |
| Mirum Pharmaceuticals Inc | Niall O’Donnell | Director | Sale of securities on an exchange or to another person at price $ 19.60 per share. | 11 Nov 2022 | 32,109 | 1,714,888 (6%) | 0% | 19.6 | 629,423 | Common Stock |
| Mirum Pharmaceuticals Inc | Niall O’Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Spruce Biosciences Inc | Niall O’Donnell | Director | 25 May 2022 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | ||
| Mirum Pharmaceuticals Inc | Niall O’Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | 13 Apr 2021 | 4,629,630 | 0 | - | - | Series A Preferred Stock | ||
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | 13 Apr 2021 | 3,710,116 | 0 | - | - | Series B Preferred Stock | ||
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | 13 Apr 2021 | 1,034,600 | 1,034,600 | - | - | Common Stock | ||
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | 13 Apr 2021 | 829,113 | 1,863,713 | - | - | Common Stock | ||
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 13 Apr 2021 | 200,000 | 2,063,713 | - | 15 | 3,000,000 | Common Stock |
| Reneo Pharmaceuticals Inc | Niall O’Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2021 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Spruce Biosciences Inc | Niall O’Donnell | Director | 14 Oct 2020 | 2,916,664 | 0 | - | - | Series B Preferred Stock | ||
| Spruce Biosciences Inc | Niall O’Donnell | Director | 14 Oct 2020 | 445,905 | 445,905 | - | - | Common Stock | ||
| Spruce Biosciences Inc | Niall O’Donnell | Director | 14 Oct 2020 | 250,000 | 695,905 | - | 15 | 3,750,000 | Common Stock | |
| Mirum Pharmaceuticals Inc | Niall O’Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,000 | 17,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges